Show results for
Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Isle Of Man
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Oncology Equipment Supplied In Europe
199 equipment items found
Manufactured by:Olink Proteomics based inUppsala, SWEDEN
The most comprehensive, high-performance protein biomarker panels available for oncology studies. The flexibility and scalability of our Olink® Explore platform can be utilized either to screen our entire library of 3072 assays, or in studies that focus on one or several of the eight Explore 384-plex panels that make up the Explore 3072 protein library. ...
Manufactured by:AJ Vaccines A/S based inKøbenhavn, DENMARK
VesiCulture (BCG Culture) For the treatment of Bladder ...
Distributed by:GPC Pharma Ecza Deposu San. Tic. Ltd. Sti. based inSariyer, TURKEY
In addition to the traditional drugs used in the treatment of oncological diseases, the frequency of which is increasing day by day, we supply global oncological drugs with smart drug technology and deliver them to the patients under favorable ...
Manufactured by:EnteroBiotix Ltd based inGlasgow, UNITED KINGDOM
Immuno-oncology exploits the mechanisms of the body’s own natural immune response, either by stimulating or suppressing it, to fight ...
Manufactured by:Hemodia SAS based inLabège, FRANCE
From the patient's preparation to the care: Syringes, needle packs; Specific implanted ports care kits dedicated to needle installation, infusion connection and disconnection; Chemotherapy decontamination kits: for carers handling cytotoxic agents. Our packs regroup all devices and consumables required for preparing and carrying out an intravenous chemotherapy session. To be totally in line with ...
by:Numares GROUP Corp based inRegensburg, GERMANY
Cancer is among the leading causes of death worldwide. Approximately 38 % of men and women will be diagnosed with cancer at some point during their lifetimes (based on 2013 – 2015 data1). Cancer can occur in any organ and in any cell type and the variability in clinical presentation makes early diagnosis difficult. Common cancers with established benefit of early diagnosis but for ...
Manufactured by:CanVirex AG based inBasel, SWITZERLAND
Oncolytic measles viruses as a multiplexed immune-modulating platform for cancer therapy. Cancer remains a medical and social burden worldwide despite several technological advances in the past decades. Conventional cancer treatments such as surgery, chemo-, or radiotherapy are restricted to local therapy or by dose-limiting toxicities and may induce drug resistance during treatment. In recent ...
by:Evaxion Biotech A/S based inHørsholm, DENMARK
PIONEER is our proprietary AI platform for the rapid discovery and design of patient-specific neoepitopes used to derive immuno-oncology therapies. It has been shown that neoepitopes, which arise from patient-specific tumor mutations, play a critical role in T-cell mediated antitumor immune ...
Manufactured by:AstraZeneca based inCambridge, UNITED KINGDOM
Mechanism: ATM inhibitor; Area under investigation: glioblastoma; Date commenced phase: Q2 2018; Estimated Filing Acceptance: US: EU: Japan: China. Additional information. Molecule size: Small molecule Status ...
Manufactured by:AstraZeneca based inCambridge, UNITED KINGDOM
Mechanism: CDK9 inhibitor Area under investigation: haematalogical malignancies Date commenced phase: Q4 2017 Estimated Filing Acceptance: US: EU: Japan: China. Additional information. Molecule size: Small molecule Status change: New to Phase ...
Manufactured by:The Menarini Group based inFlorence, ITALY
TAGRAXOFUSP is a novel targeted therapy directed to the IL-3 receptor α (CD123), a target present on a wide range of malignancies including Blastic Plasmacytoid Dendritic Nell Neoplasm (BPDCN). It comprises human IL-3 recombinantly fused to a truncated diphtheria toxin (DT) payload engineered such that IL-3 replaces the native DT receptor-binding domain. The IL-3 domain of TAGRAXOFUSP ...
Manufactured by:The Menarini Group based inFlorence, ITALY
MEN1703 is a dual kinase inhibitor targeting PIM (PIM1, PIM2, PIM 3) and FLT3 kinases. FLT3 internal tandem duplication (FLT3-ITD) is one of the most common genetic lesions in acute myeloid leukemia patients (AML) and is associated with a poor prognosis. PIM kinases are thought to be one of the major drivers of the resistance phenotype to FLT3 inhibitors and their inhibition in relapsed samples ...
Manufactured by:Teknimed based inL’union, FRANCE
F20® radiopaque bone cement is a ready to use, medium viscosity, low exothermic, self-curing bone cement with a high content of radiopaque agent for a perfect level of visualization and safety required during percutaneous vertebral bone augmentation procedures. Its composition has been optimized to get the most suitable handling properties for surgeon’s convenience. F20® comes as an ...
Manufactured by:The Menarini Group based inFlorence, ITALY
SL-901 is an oral small molecule PI3K and DNA-PK inhibitor that has demonstrated activity against PI3K α/δ and PIK3C2 β. SL-901 has shown preclinical activity against a variety of tumor types. A Phase 1 trial in patients with solid tumors is currently ...
Manufactured by:AstraZeneca based inCambridge, UNITED KINGDOM
Mechanism: BCL2/xL; Area under investigation: haematological malignancies; Date commenced phase: Q4 2019; Estimated Filing Acceptance: US: EU: Japan: China; Additional information: Partnered product. Molecule size: Small molecule; Status ...
Manufactured by:The Menarini Group based inFlorence, ITALY
Elacestrant is a selective estrogen receptor degrader (SERD) evaluated for potential use as a once daily oral treatment in patients with estrogen receptor positive (ER+)/HER2- advanced or metastatic breast cancer. Studies completed to date, including the positive results from the EMERALD phase 3 trial, indicate that the compound has the potential for use as a single agent or in combination with ...
Manufactured by:The Menarini Group based inFlorence, ITALY
NEXPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor. XPO1 is a nuclear exporter protein that transport from the nucleus to the cytoplasm several proteins, including tumor suppressors, oncogenes, and proteins involved in governing cell growth; it is often overexpressed, and its function mis-regulated in several types of cancers. By inhibiting the XPO1 protein, tumor suppressors proteins ...
Manufactured by:The Menarini Group based inFlorence, ITALY
MEN1309 is an antibody-drug conjugate (ADC) constituted by a fully human IgG1 antibody conjugated through a cleavable linker to a cytotoxic agent (a maytansin derivative, DM4), responsible for its antitumor activity. The target antigen, CD205, is highly expressed in a wide range of both solid and hematological cancer cells. Once MEN1309 binds its target, the MEN1309/CD205 complex is rapidly ...
Manufactured by:STERYLAB S.r.l. based inRHO - (MILAN), ITALY
The design of BEST-LISAS® is the most advanced to date and guarantees to the physician the following ...
by:Italfarmaco SpA based inMilan, ITALY
AKYNZEO® (netupitant/palonosetron) is the first and only fixed-dose antiemetic in combining the new NK-1 antagonist netupitant with the sole antagonist of the second generation of serotonin, palonosetron, already marketed by Italfarmaco since 2006 as ALOXI®. Thanks to its totally innovative oral formulation and to the characteristics of its active ingredients, which act in a synergistic ...